Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana. The abstract is available on the DDW web site at http://www.ddw.org.
“These data have been used to inform the design of our ongoing Phase 2a study.”
Alvine's abstract, entitled: "ALV003, a Mixture of Two Oral Proteases, Degrades Immunogenic Gluten Epitopes in a Complex Food Environment" was presented Sunday, May 2nd, 2010. Alvine scientists reported on a simple gastric digestion model they developed to study the ability of ALV003 to degrade gluten in the context of a complex meal.
"The data derived from the gastric simulation model were consistent with in vivo data from a Phase 1 study, with comparable degrees of gluten degradation observed," said Daniel C. Adelman, M.D., Alvine's Senior Vice President of Development and Chief Medical Officer. "These data have been used to inform the design of our ongoing Phase 2a study."
The current Phase 2a study is double-blind, placebo-controlled and is being conducted in well-controlled celiac disease patients receiving a daily gluten challenge for six weeks.
SOURCE Alvine Pharmaceuticals, Inc.
SU2C announces grants to support cutting-edge research in a variety of cancers